Once again, the laymen on this board miss the whole purpose of this press release..
This technology is a required step in determining and ultimately propagating specific HLA haplotypes. If you remember or had any classes in immunology, then you would recall that tissue rejection is one of the top problems going forward with stem cells, specifically with the use of embryonic stem cells. Unless you save cells from your own birth embryo, you must take immunsurpressive drugs (assuming the HLA haplotype is not a match). This is restricting.
The ability to have a massive tissue bank, covering all the possible haplotypes is a patent attorneys wet dream. You would corner the whole market going forward, regardless of whether it is your own commercial product or not. This technology WILL show up in a patent, just give it 16 months to publish. If it issues, all future therapies that are not in an immune priviledged location (read as...everywhere but the eye) will be subject to this patents claim scope.
Is this PR going to move the average number cruncher on wall street or wannabe day trader in his moms basement..absolutely not. But if you know where this market MUST go in the future, you would realize what they are telling you here. Patentability and commercialization road blocks for all future technologies. And yes, I am a biotech patent attorney..just to pre-empt the anticipated responses...
“Producing millions of patient-specific stem cell lines is commercially unviable,” stated William M. Caldwell, CEO and Chairman of ACTC. “However, we are optimistic that we will soon have at least two different methods to create stem cells banks to match patients. We estimate that a bank of 100 different lines could furnish a complete tissue (HLA haplotype) match for half of the US population. This will allow us to expand the range of possible clinical therapies to include diseases such as diabetes and heart disease.”
A lot of this science, and these patents, will be useful all over the globe, not just here in the U.S. And that's also exciting. Science is valuable, and this science is going to be transformative and so great for people.
But there are, no doubt, interests who don't want curative science to prevail. They know they may eventually have to get in, but they'd like to see the old business model go a bit longer.
But our nation has to jump on board the train of good science, and the ethical scientific opportunities that this company offers, ultimately - I think and believe.